Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.

Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, Molho RB, Itai A, Modiano TM, Gold R, Kaufman B, Shimon SP.

Breast. 2018 Aug;40:141-146. doi: 10.1016/j.breast.2018.05.007. Epub 2018 May 22.

PMID:
29800932
2.

Symptom cluster of emotional distress, fatigue and cognitive difficulties among young and older breast cancer survivors: The mediating role of subjective stress.

Levkovich I, Cohen M, Alon S, Kuchuk I, Nissenbaum B, Evron E, Pollack S, Fried G.

J Geriatr Oncol. 2018 Sep;9(5):469-475. doi: 10.1016/j.jgo.2018.05.002. Epub 2018 Aug 6.

PMID:
29759914
3.

Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.

Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, Addison CL, Kuchuk I, Zhu X, Gelmon K, Arnaout A.

Cancer Metastasis Rev. 2016 Sep;35(3):427-37. doi: 10.1007/s10555-016-9631-3. Review.

PMID:
27405651
4.

Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study.

Arnaout A, Kuchuk I, Bouganim N, Pond G, Verma S, Segal R, Dent S, Gertler S, Song X, Kanji F, Clemons M.

Curr Oncol. 2016 Jun;23(3):e276-9. doi: 10.3747/co.23.2394. Epub 2016 Jun 9.

5.

A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.

Jacobs C, Kuchuk I, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, Dent S, Gertler S, Verma S, Song X, Simos S, Cella D, Clemons M.

Breast Cancer Res Treat. 2016 Jan;155(1):77-84. doi: 10.1007/s10549-015-3646-2. Epub 2015 Dec 7.

PMID:
26643085
6.

[THE CURRENT APPROACH TO METASTATIC RENAL CELL CARCINOMA].

Keizman D, Maimon N, Mishaeli M, Kuchuk I, Gottfried M.

Harefuah. 2015 Aug;154(8):535-9. Review. Hebrew.

PMID:
26480622
7.

Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making.

Hutton B, Clemons M, Mazzarello S, Kuchuk I, Skidmore B, Ng T.

Cancer Treat Rev. 2015 Dec;41(10):951-9. doi: 10.1016/j.ctrv.2015.09.007. Epub 2015 Sep 30. Review.

PMID:
26442474
8.

The incidence and clinical impact of bone metastases in non-small cell lung cancer.

Kuchuk M, Kuchuk I, Sabri E, Hutton B, Clemons M, Wheatley-Price P.

Lung Cancer. 2015 Aug;89(2):197-202. doi: 10.1016/j.lungcan.2015.04.007. Epub 2015 May 11.

PMID:
26003503
9.

Evaluating the feasibility of performing window of opportunity trials in breast cancer.

Arnaout A, Robertson S, Kuchuk I, Simos D, Pond GR, Addison CL, Namazi M, Clemons M.

Int J Surg Oncol. 2015;2015:785793. doi: 10.1155/2015/785793. Epub 2015 Jan 20.

10.

Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.

Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, Kuchuk I, Hourvitz A, Levron J, Mozer-Mendel M, Brengauz M, Biderman H, Manela D, Catane R, Dor J, Orvieto R, Kaufman B.

Fertil Steril. 2014 Aug;102(2):488-495.e3. doi: 10.1016/j.fertnstert.2014.05.017. Epub 2014 Jun 14.

PMID:
24934489
11.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.

12.

Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.

Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, Bouganim N, Vandermeer L, Clemons M.

Oncologist. 2014 Feb;19(2):127-34. doi: 10.1634/theoncologist.2013-0359. Epub 2014 Jan 28.

13.

Does estrogen play a role in response to adjuvant bone-targeted therapies?

Russell K, Amir E, Paterson A, Josse R, Addison C, Kuchuk I, Clemons M.

J Bone Oncol. 2013 Jul 5;2(4):167-73. doi: 10.1016/j.jbo.2013.06.001. eCollection 2013 Dec. Review.

14.

Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers.

Kuchuk I, Beaumont JL, Clemons M, Amir E, Addison CL, Cella D.

J Bone Oncol. 2013 Aug 8;2(4):154-7. doi: 10.1016/j.jbo.2013.07.004. eCollection 2013 Dec.

15.

Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.

Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M.

J Bone Oncol. 2013 Oct 3;2(4):137-44. doi: 10.1016/j.jbo.2013.09.001. eCollection 2013 Dec.

16.

Preference weights for chemotherapy side effects from the perspective of women with breast cancer.

Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent SF, Song X, Segal R, Mazzarello S, Crawley F, Dranitsaris G, Clemons M.

Breast Cancer Res Treat. 2013 Nov;142(1):101-7. doi: 10.1007/s10549-013-2727-3. Epub 2013 Oct 16.

PMID:
24129976
17.

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.

Hutton B, Morretto P, Emmenegger U, Mazzarello S, Kuchuk I, Addison CL, Crawley F, Canil C, Malone S, Berry S, Fergusson D, Clemons M.

J Bone Oncol. 2013 Jun 21;2(3):105-9. doi: 10.1016/j.jbo.2013.05.002. eCollection 2013 Sep.

18.

Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists.

Kuchuk I, Mazzarello S, Butterfield K, Appleton A, Addison CL, Clemons M.

J Bone Oncol. 2013 Jan 1;2(1):38-46. doi: 10.1016/j.jbo.2012.12.001. eCollection 2013 Feb. Review.

19.

Incidence and consequences of bone metastases in lung cancer patients.

Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P.

J Bone Oncol. 2013 Jan 17;2(1):22-9. doi: 10.1016/j.jbo.2012.12.004. eCollection 2013 Feb.

20.

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases.

Simos D, Addison CL, Kuchuk I, Hutton B, Mazzarello S, Clemons M.

J Clin Med. 2013 Aug 19;2(3):67-88. doi: 10.3390/jcm2030067. Review.

21.

A national portfolio of bone oncology trials-The Canadian experience in 2012.

Kuchuk I, Simos D, Addison CL, Clemons M.

J Bone Oncol. 2012 Oct 17;1(3):95-100. doi: 10.1016/j.jbo.2012.09.001. eCollection 2012 Dec. Review.

22.

Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients-preliminary results.

Fralick M, Bouganim N, Kremer R, Kekre N, Robertson S, Vandermeer L, Kuchuk I, Li J, Murshed M, Clemons M.

J Bone Oncol. 2012 Dec 1;1(3):69-73. doi: 10.1016/j.jbo.2012.10.003. eCollection 2012 Dec.

23.

Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer?

Kuchuk I, Clemons M, Addison C.

Curr Oncol. 2012 Oct;19(5):e303-4. doi: 10.3747/co.19.1009. No abstract available.

24.

Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?

Simmons CE, Kuchuk I, Freedman OC, Colgan T, Dodd A, Kulhanek K, Sheiner J, Dranitsaris G, Dowsett M, Folkerd E, Clemons MJ.

Clin Oncol (R Coll Radiol). 2012 Oct;24(8):e128-9. doi: 10.1016/j.clon.2012.06.009. Epub 2012 Jul 12. No abstract available.

PMID:
22795828
25.

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J.

Clin Cancer Res. 2010 May 1;16(9):2646-55. doi: 10.1158/1078-0432.CCR-10-0041. Epub 2010 Apr 20.

26.

Outcome of thick (> 4 mm) node-negative melanomas.

Zippel DB, Shapira R, Kuchuk I, Goitein D, Winkler E, Papa MZ, Schachter J.

Isr Med Assoc J. 2009 Nov;11(11):669-72.

27.

Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Nun AB, Kuchuk I, Shimoni A, Nagler A, Schachter J.

J Immunother. 2009 May;32(4):415-23. doi: 10.1097/CJI.0b013e31819c8bda.

PMID:
19342963
28.

Unique spectrum of MEFV mutations in Iranian Jewish FMF patients--clinical and demographic significance.

Shinar Y, Kuchuk I, Menasherow S, Kolet M, Lidar M, Langevitz P, Livneh A.

Rheumatology (Oxford). 2007 Nov;46(11):1718-22. Epub 2007 Oct 15.

PMID:
17938136
29.

[Clinico-morphologic parallels of prostatic adenoma in various age groups].

Kuchuk IaI.

Urol Nefrol (Mosk). 1989 Mar-Apr;(2):64-8. Review. Russian. No abstract available.

PMID:
2471343

Supplemental Content

Loading ...
Support Center